Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
The purpose of this study is to determine the best management strategy to maintain remission in patients with ANCA vasculitis who have been treated with rituximab induced B cell depletion for at least two years. This study will compare intermittent B Cell depletion upon B cell return or intermittent B cell depletion upon serologic relapse.
Epistemonikos ID: dbae4d4d29ab28f52ff749d722f737ff0ed39541
First added on: May 12, 2024